Merck & Company, Inc. Common Stock (new)

Merck’s moat rests on a mix of strong intangible assets, switching costs in oncology, efficient scale in vaccines and manufacturing, and growing modality breadth.

Intangible assets: 85/100. Keytruda is approved across many tumors and now has the FDA‑approved subcutaneous Keytruda Qlex across most solid tumor indications, plus EU approval of an SC route, reinforcing brand equity and life‑cycle protection.

Patents still guard many assets, though Keytruda composition of matter will face U.S. expiry enabling biosimilars by late 2028 to 2029. Switching costs: 75/100. In cancer, entrenched regimens, diagnostics, and multidisciplinary practice patterns create meaningful but not insurmountable switching costs; Qlex’s convenience should help.

Cost advantage and efficient scale: 70/100. Global manufacturing, vaccine know‑how and commercial infrastructure provide scale economies and barriers, evidenced by sustained gross margins and rapid, multi‑indication launches. Network effects: 20/100. Pharma generally lacks classic network effects.

Weighted overall moat score reflects heavier weight on intangible assets and switching costs given oncology leadership and vaccines manufacturing depth, offset by the finite patent clock on Keytruda.

Keytruda exhibits strong pricing power anchored in clinical outcomes and breadth of labels, and the Qlex formulation adds convenience value.

However, IRA price setting begins to affect select Part D drugs and is expected to reach Part B in 2028; Merck notes Lenvima is selected for price setting in 2028 and expects Keytruda selection with price effective 2029, which, together with biosimilar competition, constrains long‑run pricing.

Vaccines like Gardasil historically carried pricing power, but China dynamics and local competition are near‑term offsets. Overall we score pricing power as solid but moderating into the LOE window.

Merck’s revenue base is diversified across oncology, vaccines, specialty, and animal health, but Keytruda concentration at 49 percent of sales in 2025 reduces medium‑term predictability ahead of biosimilars.

New growth pillars improve visibility: Winrevair reached roughly 1.44 billion dollars in 2025 sales, Verona’s Ohtuvayre adds a commercial COPD asset, and the Terns deal and Daiichi ADCs extend oncology. China Gardasil variability and IRA timing inject uncertainty.

Net, we view the long‑term growth trajectory as positive but with a 2028 to 2029 step‑down risk, meriting a mid‑60s score.

Balance sheet and cash generation are robust. Year‑end 2025 cash and equivalents were about 14.6 billion dollars, debt carrying value about 49.3 billion dollars, and cash from operations 16.5 billion dollars. Capex was 4.1 billion dollars, implying TTM FCF around 12.4 billion dollars.

Merck plans about 20 billion dollars of capital projects during 2025 to 2029, mostly U.S., while still funding R&D and shareholder returns. Dividend cash outlay was approximately 8.2 billion dollars in 2025. This profile supports resilience into policy and LOE headwinds.

Merck has balanced organic reinvestment with disciplined M&A and collaborations. R&D expenses were about 15.0 billion dollars in 2025, reflecting sustained internal investment.

Externally, Merck acquired Verona (COPD, ~10 billion dollars, closed Oct 2025), is acquiring Terns (CML candidate, ~6.7 billion dollars, announced Mar 2026), added Elanco’s aqua business to Animal Health, and executed a major ADC collaboration with Daiichi Sankyo.

Shareholder returns remained active with roughly 5.1 billion dollars of share repurchases in 2025 and a rising dividend per share. Occasional one‑time charges and 2023 IPR&D expense spikes reflect the strategy’s aggressiveness, but we view the portfolio build as sensible ahead of Keytruda LOE.

Leadership has executed well on lifecycle management, label expansion and business development while maintaining investment capacity. The Keytruda Qlex approval demonstrates operational excellence and life‑cycle thinking. Management’s clear disclosures on LOE, IRA exposure and China vaccine dynamics show realistic risk framing.

While not founder‑led, Merck’s culture, governance and capital allocation history support long‑term stewardship. We score management above average, with room to prove post‑2029 trajectory.